Gilbert Cisneros
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Cisneros sold $1K–$15K in $JNJ and PFE on Jan 24, 2025 — 12 days before the No Tax Breaks for Outsourcing Act (S409) was introduced, a bill that raises taxes on foreign profits and could hurt companies with large offshore operations.
Rep. Cisneros bought $1K–$15K in $MSFT on Jan 24, 2025 — 13 days before the Growing and Preserving Innovation in America Act (HR1062) was introduced, a bill that permanently locks in higher tax deductions for U.S. corporations like Microsoft.
Rep. Cisneros bought $15K–$50K in $UNH on Jan 24, 2025 — 20 days before the I CAN Act (HR1317) was introduced, a bill that expands nurse practitioner scope under Medicare/Medicaid, potentially lowering labor costs for insurers like UnitedHealth.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $HE | Hawaiian Electric Industries, Inc. Common Stock (HE) [ST] | $50K-$100K | — | — | — | Jan 31, 2025 |
| BUY | $CACI | CACI International, Inc. Class A Common Stock (CACI) [ST] | $15K-$50K | — | $501.90 | — | Jan 31, 2025 |
| BUY | $UNH | UnitedHealth Group Incorporated Common Stock (UNH) [ST] | $15K-$50K | $532.51 | $368.05 | -30.9% | Jan 24, 2025 |
| BUY | $WTW | Willis Towers Watson Public Limited Company - Ordinary Shares (WTW) [ST] | $15K-$50K | $326.07 | $289.34 | -11.3% | Jan 13, 2025 |
| BUY | $AGIO | Agios Pharmaceuticals, Inc. - Common Stock (AGIO) [ST] | $1K-$15K | $33.73 | $24.43 | -27.6% | Jan 29, 2025 |
| BUY | $APG | APi Group Corporation Common Stock (APG) [ST] | $1K-$15K | — | — | — | Jan 7, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [OP](Stock Option) | $1K-$15K | — | — | — | Jan 29, 2025 |
| BUY | $KMX | CarMax Inc (KMX) [ST] | $1K-$15K | $78.50 | — | — | Jan 13, 2025 |
| BUY | $STZ | Constellation Brands, Inc. Common Stock (STZ) [OP](Stock Option) | $1K-$15K | $185.91 | — | — | Jan 13, 2025 |
| BUY | $CRNX | Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) [ST] | $1K-$15K | $39.38 | — | — | Jan 29, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Unplug the Electric Vehicle Charging Stations Program Act
H.R. 1513 targets $7.5 billion in federal EV charging grants for repeal. The bill is in early committee stage but has a companion Senate bill, increasing its probability of advancement. Pure-play charging companies EVgo, ChargePoint, and Blink face direct revenue risk from the loss of NEVI and CFI capital co-funding. Tesla faces indirect headwinds from slower EV adoption, though its proprietary Supercharger network and vehicle sales buffer the impact.
National Right-to-Work Act
The National Right-to-Work Act (HR1232) is an early-stage bill in the 119th Congress with 123 cosponsors, referred to the House Education and Workforce Committee. It would eliminate mandatory union fees in the private sector, structurally benefiting unionized employers like UPS, FDX, GM, and F over the long term. However, legislative odds are very low in this Congress; market data shows recent stock gains for these tickers are driven by broader sector momentum, not this bill.
SAFE Act
The SAFE Act expands Medicare to cover fall risk assessments and prevention services provided by physical and occupational therapists, effective January 2026. This creates a new reimbursable service line for outpatient therapy clinics like $USPH and increases staffing demand for agencies like $AMN. The bill is in early committee stage with bipartisan support (51 cosponsors) and a Senate companion, but no funding is authorized.
No Tax Breaks for Outsourcing Act
The No Tax Breaks for Outsourcing Act (S409) would eliminate tax deferral on foreign profits for U.S. multinationals, increasing effective tax rates by 5-8 percentage points. The bill is in early stages (referred to Senate Finance Committee, 19 cosponsors) and poses a 4-8% annual net income headwind for high international-exposure companies. Despite 8-30% rallies in the last 30 days across MSFT, AAPL, GOOGL, KO, PG, XOM, and CVX, this legislative risk is not currently priced into valuations.
National Plan for Epilepsy Act
S.494, the National Plan for Epilepsy Act, is an early-stage coordination bill with zero authorized spending. It creates an advisory council and mandates federal research coordination for epilepsy but appropriates no funds. Market impact is negligible — no direct revenue driver for any public company.
Broadband Grant Tax Treatment Act
The Broadband Grant Tax Treatment Act (S.674) proposes to exclude federal and state broadband grants from gross income, effectively increasing their value by the corporate tax rate. The bill is in an early legislative stage (referred to Senate Finance Committee). Tower REITs CCI, AMT, and SBAC are structurally positioned to benefit from accelerated grant-funded deployments, but no near-term market impact is expected. Recent price data shows mixed performance across the sector over the last 7 days.
Growing and Preserving Innovation in America Act of 2025
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
Alternatives to PAIN Act
The Alternatives to PAIN Act (HR1227) is an early-stage House bill that would eliminate deductibles and lower co-pays for non-opioid pain management drugs under Medicare Part D, effective January 1, 2026. The bill has been referred to two committees with no further action since February 2025. Market impact on Part D sponsors (UNH, CVS, HUM, CI) is currently negligible because the bill is unfunded, in early legislative stages, and faces an uncertain path to enactment.
Lung Cancer Screening and Prevention Act of 2025
HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.
I CAN Act
The I CAN Act (HR1317) structurally lowers healthcare labor costs by expanding APRN scope under Medicare/Medicaid, directly benefiting managed care insurers. Real market data confirms managed-care insurers $CNC (+27.93% 7-day, +63.41% 30-day), $MOH (+10.81% 7-day, +46.26% 30-day), and $HUM (+12.05% 7-day, +39.09% 30-day) are already pricing in this regulatory tailwind. The bill is early-stage but has a companion in the Senate and executive-order tailwinds — pure-play Medicaid/Medicare insurers are the structural winners.
Other Filings by Gilbert Cisneros
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.